TrialBMC medicine2023

Safety, tolerability, pharmacokinetics, and antiviral activity of the novel core protein allosteric modulator ZM-H1505R (Canocapavir) in chronic hepatitis B patients: a randomized multiple-dose escalation trial.

Haiyan Jia et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.